Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment - PACE-CME

Diabetic patients with chronic kidney disease may benefit more from GLP analogue treatment

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC.25
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
- Darren K. McGuire, MD
Expert opinion on the SOUL study results
Expert opinion on the SOUL study results
ACC.25
Expert opinion on the SOUL study results
- Gina Lundberg, MD
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
MinuteCE®
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits